Clinical Trial Update: Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two doses of anifrolumab versus placebo in adults with active proliferative lupus nephritis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Lupus Nephritis | Phase 2 | Status: COMPLETED | Results posted: 2021-11-24